Johnson Matthey has worked with more than 500 million medical components for “electrophysiology, vascular intervention, cardiac rhythm management, neuromodulation and cochlear therapy areas,” according to its website.
The deal could reach hundreds of millions of dollars, the news outlet reported May 31.
Goldman Sachs Group is teed up to coordinate the purported sale, and neither company commented on the matter.
